In the last trading session, 1.98 million Travere Therapeutics Inc (NASDAQ:TVTX) shares changed hands as the company’s beta touched 0.72. With the company’s per share price at $13.99 changed hands at -$0.02 or -0.14% during last session, the market valuation stood at $1.07B. TVTX’s last price was a discount, traded about -9.79% off its 52-week high of $15.36. The share price had its 52-week low at $5.12, which suggests the last value was 63.4% up since then. When we look at Travere Therapeutics Inc’s average trading volume, we note the 10-day average is 2.23 million shares, with the 3-month average coming to 1.47 million.
Analysts gave the Travere Therapeutics Inc (TVTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.47. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TVTX as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. Travere Therapeutics Inc’s EPS for the current quarter is expected to be -0.67.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX was in red as seen at the end of in last trading. With action -3.58%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 55.62%, with the 5-day performance at -3.58% in the red. However, in the 30-day time frame, Travere Therapeutics Inc (NASDAQ:TVTX) is 49.47% up. Looking at the short shares, we see there were 8.66 million shares sold at short interest cover period of 5.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 20.5, meaning bulls need an upside of 31.76% from its current market value. According to analyst projections, TVTX’s forecast low is 12 with 28 as the target high. To hit the forecast high, the stock’s price needs a -100.14% plunge from its current level, while the stock would need to tank 14.22% for it to hit the projected low.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Data shows that the Travere Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 91.38% over the past 6 months, a 22.09% in annual growth rate that is considerably higher than the industry average of 17.70%. Year-over-year growth is forecast to reach 55.90% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 60.87M. 13 analysts are of the opinion that Travere Therapeutics Inc’s revenue for the current quarter will be 67.21M. The company’s revenue for the corresponding quarters a year ago was 37.09M and 45.06M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 64.10%. The estimates for the next quarter sales put growth at 49.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.34%. The 2024 estimates are for Travere Therapeutics Inc earnings to decrease by -131.22%.
TVTX Dividends
Travere Therapeutics Inc is expected to release its next quarterly earnings report in November.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30.
